The difference between pharmaceutical intermediates and active pharmaceutical ingredients

The core difference between pharmaceutical intermediates and active pharmaceutical ingredients (APIs) is that intermediates are intermediate products in the synthesis process of APIs and require further processing;

2025

07-14

Overview and Differences of Drug Raw Materials, Intermediates, and Finished Products

In the drug manufacturing process, raw materials, intermediates, and finished products are three important stages.

2025

07-14

2020 China Oncology Special Drug Payment Report Released, Foreseeing the Integration Development Path of the Pharmaceutical Insurance Industry

With the continuous advancement of the "Healthy China 2030" strategy, a multi-level security model is becoming a new trend. How to coordinate various industries to jointly contribute has become a focus for industry insiders. On September 21, Shanghai Pharmaceuticals Holding, China Re Life Insurance, Magnesium Health, and BCG jointly held the "Summit Forum on Building a Multi-level Medical Security System — and the 2020 China Oncology Special Drug Payment Report Release Conference," discussing the challenges and opportunities of the multi-level medical security system with 200 industry elites. At the meeting, Li Yongzhong, Executive Director and Vice President of Shanghai Pharmaceuticals and General Manager of Shanghai Pharmaceuticals Holding, attended and delivered a speech. "In recent years, the state has continuously..."

2020

10-15

Research finds that vitamin D extends the survival time of cancer patients

Doctors at Michigan State University have found that taking vitamin D for at least three years can help cancer patients live longer. The study results indicate that in addition to promoting bone health, vitamin D also has significant benefits. These findings were presented at the American Society of Clinical Oncology annual meeting on June 3, 2019. According to data from the Centers for Disease Control and Prevention,

2020

10-15

The 5th China Pharmaceutical Innovation and Investment Conference Held to Support Pharmaceutical Innovation Development

China News Service, September 30 - On September 27, the 5th China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the "Venture Capital Conference") was held in Suzhou Industrial Park. This conference was jointly organized by the China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China Pharma Promotion Association"), China Medical Device Industry Association, Hong Kong Stock Exchange, and Aimeda Pharmaceutical Consulting. The conference attracted nearly 2,000 participants from over 100 representatives of domestic and international investment institutions, pharmaceutical innovation enterprises, and research institutes. Song Ruilin, Executive President of the China Pharmaceutical Innovation Promotion Association, stated that this Venture Capital Conference implements the goal of "promoting the integration of domestic and international social capital with pharmaceutical innovation, enhancing our country's

2020

10-15

Overview of Obesity Treatment Drug Development and Market Outlook

Obesity refers to an excessive total body fat content and/or increased local fat content with abnormal distribution. It is a chronic metabolic disease caused by the combined effects of genetic and environmental factors. Obesity mainly includes three characteristics: an increase in the number of fat cells, dysregulation of body fat distribution, and local fat accumulation. According to the latest study on BMI trends in all countries worldwide based on weight and height data from 128.9 million children, adolescents, and adults, the prevalence of obesity has increased in most countries globally from 1975 to 2016. Global data published by The Lancet in 2014 showed: 19

2020

10-15

The pharmaceutical industry has long been favorable, with leading companies gradually entering the value range.

Based on the long-term growth potential of the pharmaceutical industry, GF Fund plans to launch its second actively managed pharmaceutical-themed fund, GF Pharmaceutical Health Mixed Fund, on October 13. The proposed fund manager, Wu Xingwu, stated that the long-term logic of the current pharmaceutical market remains unchanged. In the long run, within sub-sectors such as innovative drug supply chains, medical services, and high-end equipment, outstanding companies have the space and opportunity to grow larger and stronger. The industry's long-term positive logic remains unchanged. Affected by the COVID-19 pandemic, the pharmaceutical and biotechnology sector became a highlight in the A-share market in the first half of the year. "The long-term development logic of the pharmaceutical industry has not changed," Wu Xingwu said.

2020

10-15

A new weapon in diabetes treatment! HuaLing Pharmaceuticals' globally first innovative drug Dozaglitazone obtains the "Drug Manufacturing License"

Today, Hua Medicine announced that after the review of the Marketing Authorization Holder (MAH) system and on-site inspection, the company has obtained the "Drug Manufacturing License" for the globally first-in-class innovative drug dorzagliatin issued by the Shanghai Municipal Drug Administration. Dorzagliatin is a globally first-in-class dual-action glucokinase activator under development, aimed at controlling the progressive degenerative disease of diabetes by restoring glucose homeostasis in patients with type 2 diabetes. By repairing the defect in the glucose sensor function of glucokinase, dorzagliatin has the ability to restore type 2

2020

10-15